藍光發展(600466.SH):擬轉讓迪康藥業股權 預計增加當期損益2.47億元
格隆匯 7 月 28日丨藍光發展(600466.SH)公佈,公司及成都藍迪共享企業管理合夥企業(有限合夥)(“藍迪共享”)擬將合計持有的成都迪康藥業股份有限公司(“目標公司”)100%的股權轉讓給漢商集團股份有限公司(“漢商集團”)和漢商大健康產業有限公司(“漢商大健康”)。
此次交易有利於公司集中資源專注於核心業務的經營和拓展,實現公司高度聚焦住宅地產開發和現代服務業的戰略目標。
此次交易預計使公司當期損益增加約2.47億元,具體金額以公司年審會計師審計結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.